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Three years have passed since mutations of the tyrosine kinase domain 
of the epidermal growth factor receptor (EGFR) were discovered in 
patients with lung cancer who had dramatic clinical responses to treat-
ment with geﬁtinib. Additional laboratory and clinical studies have 
provided further insights into the biological impact of EGFR mutations 
in cell culture experiments and in patients with lung cancer. In vitro 
characterizations of lung cancer cell lines and host cell lines transfected 
with these mutant and wild type EGFRs show most cell lines with mu-
tated EGFRs are growth inhibited by 10-100 fold lower concentrations 
of geﬁtinib and erlotinib (10-100 nM) compared to wild type EGFR 
(Approximately 1-5 uM). Lung cancer cell lines with mutations of the 
EGFR treated with concentrations of geﬁtinib and erlotinib that are 
achievable in the plasma undergo apoptosis rather than growth arrest. 
The other common genomic changes that arise in adenocarcinomas of 
the lung that have an impact on tyrosine kinase inhibitors and other 
targeted agents include KRAS, BRAF, and LKB1. 
Prospective studies of lung cancer patients with EGFR mutations 
treated with geﬁtinib and erlotinib have reported a close association 
between EGFR mutations, increased chance of clinical response and 
longer survival. Patients with EGFR mutations treated with geﬁtinib or 
erlotinib have a response rate of approximately 80%, a median time to 
progression in excess of approximately one year, and a median survival 
in excess of two years. This has led to the development of commercial 
tests to determine if the DNA from tumors retrieved from patients with 
adenocarcinoma have a mutation of the EGFR. 
The genomic change associated with resistance to treatment with 
geﬁnib and erlotinib is a DNA mutation which changes the threonine 
to methionine at the 790th amino acid of EGFR known as the (T790M) 
mutation as well as ampliﬁcation of the MET oncogene. Irreversible in-
hibitors including HKI-272 and PF-299804 can cause growth inhibition 
in NSCLC cell lines with both the resistance and sensitizing mutations, 
while geﬁtinib and erlotinib do not. HKI-272 and PF-299804 entered 
directed phase I and phase II trials in patients previously treated with 
geﬁtinib and erlotinib and we await the results of the trials. 
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The toxicities of dyspnea, hypoxia, pneumonitis, and/or ﬁbrosis related 
to thoracic radiotherapy have been observed for many years. Toxicities 
are generally graded by using the NCI Common Toxicity Criteria or the 
WHO toxicity criteria (http://www.fda.gov/cder/cancer/toxicityframe.
htm). Dose-volume histograms have been developed to evaluate the 
volume of lung receiving various doses of radiation. The V
20
 is the per-
centage of lung volume that receives a radiation dose of 20 Gy or more. 
In general, the larger the V
20
 volume, the higher the risk of radiation 
pneumonitis, and V
20
 volume of 35% or more are associated with high 
risk of acute radiation pneumonitis and late scarring (1). Acute radia-
tion pneumonitis occurs within 1-3 months of radiotherapy, and may 
develop in 5-15% of patients. Direct injury to endothelial and epithelial 
cells may result in radiographic ﬁndings of pulmonary inﬁltrates in the 
ﬁeld of radiation, but also “out of ﬁeld” responses have been described 
and biopsies demonstrate a bronchiolitis obliterans organizing pneumo-
nitis (BOOP) like reaction (also called cryptogenic organizing pneumo-
nia – COP). The RTOG evaluated acute and late (90 days from start of 
RT) pulmonary toxicities associated with 5 completed trials of thoracic 
radiotherapy with sequential or concurrent chemotherapy (2). Acute 
pulmonary toxicity of grade 3 or greater occurred in 4-7% of partici-
pants. Late pulmonary toxicities occurred in 10-21% of patients. Severe 
late lung toxicity was greater in trials with concurrent chemotherapy 
and hyperfractionated RT, as well as induction chemotherapy followed 
by concurrent chemoradiotherapy (one daily). Sequential chemotherapy 
and radiotherapy had lower rates of late pulmonary toxicity (10%). Ste-
reotactic body radiation therapy (SBRT) is being utilized with increas-
ing frequency, especially for medically inoperable lung cancer patients. 
With this technology, large dose fractions are given to very localized 
ﬁelds. In a phase II trial of SBRT, investigators administered 60-66 
Gy in 3 fractions over 1-2 weeks (3). Grade 3-5 toxicity occurred in 
14 of 70 patients enrolled. Toxicity was greater with centrally located 
tumors as compared to the peripheral cancers. There were 6 treatment 
related deaths. Four of these deaths were associated with pneumonia. 
This increased toxicity with centrally located tumors is due to bronchial 
stenosis and scarring due to the high dose of radiation. 
Gemcitabine
Gemcitabine pulmonary toxicity has been reported in 1-3% of patients 
treated with this agent and may be fatal. The CT features include 
ground-glass opacities, thickened septal lines and reticular opaci-
ties. The distribution is diffuse and bilateral. Gemcitabine pulmonary 
toxicity may be difﬁcult to differentiate from viral pneumonitis. It is 
important to discontinue treatment as soon as it is suspected because an 
additional treatment may prove to be fatal. In severe cases, corticoste-
roids are usually given although their efﬁcacy is uncertain. 
Gemcitabine is a potent radiation sensitizer with recall phenomena. 
The maximum dose of gemcitabine given with concurrent thoracic 
radiotherapy is substantially attenuated, from the usual doses when 
given alone, because of the risk of pneumonitis. In a phase I trial of the 
CALGB, the maximum tolerated dose of twice weekly gemcitabine 
was 35 mg/m2 (70 mg/m2/week) given with concurrent thoracic radio-
therapy (4). In a phase II trial with gemcitabine (600 mg/m2 on d 1, 8) 
and cisplatin given concurrent with thoracic radiotherapy, grade 3-4 
dyspnea was observed in 14 of 62 (23%) of participants (5). 
Taxanes
The taxanes, paclitaxel and docetaxel, are widely used in treatment 
of lung cancer. Acute type I hypersensitivity reaction with paclitaxel 
are well known. Pulmonary inﬁltrates following treatment have been 
reported in low frequency with paclitaxel and somewhat more cases 
following docetaxel treatment. Docetaxel has also been associated with 
the development of pleural effusions. The combination of docetaxel and 
gemcitabine has been tested in a phase II trial by Japan Lung Cancer 
Cooperative Group. They observed an unexpectedly high rate of grade 
3 interstitial lung disease of 11% (7 of 63 patients) with this combina-
tion (6). Others have also reported high pulmonary toxicity with this 
combination. Sekine and associates observed pneumonitis in 24% (14 
of 59) of Japanese patients treated with consolidative docetaxel fol-
lowing concurrent chemoradiotherapy with other agents (7). Similarly, 
the Hoosier Oncology Group reported pulmonary toxicity in 10% of 
patients receiving consolidative docetaxel (8). 
